📊 EBS Key Takeaways
Is Emergent BioSolutions Inc. (EBS) a Good Investment?
Emergent BioSolutions demonstrates solid fundamental health with strong profitability recovery (Net Income +127.6% YoY) and excellent cash generation (FCF $156.8M, 21.1% margin). The company maintains a fortress balance sheet with 5.01x current ratio and generates substantial operating cash flow, though revenue stagnation (+0.0% YoY) and elevated leverage (1.13x Debt/Equity) present near-term headwinds.
Emergent BioSolutions shows a meaningful improvement in earnings and cash generation, with net income more than doubling year over year and free cash flow reaching a strong 21.1% margin. However, revenue was flat, leverage remains elevated, and interest coverage is only moderate, which limits the strength of the improvement and suggests the turnaround still needs to prove durability.
Why Buy Emergent BioSolutions Inc. Stock? EBS Key Strengths
- Exceptional net income growth of 127.6% YoY demonstrates operational leverage and margin expansion
- Strong free cash flow generation of $156.8M with 21.1% FCF margin provides financial flexibility
- Excellent liquidity position with 5.01x current ratio and $205.4M cash supports operations and debt service
- Operating margin of 13.5% with 35.1% gross margin indicates pricing power and cost management
- High interest coverage of 4.1x ensures debt sustainability despite elevated leverage
- Strong free cash flow generation with $156.8M of free cash flow and a 21.1% FCF margin
- Excellent near-term liquidity, supported by a 5.01x current ratio and $205.4M in cash
- Profitability improved materially year over year, with net income and diluted EPS both up more than 125%
EBS Stock Risks: Emergent BioSolutions Inc. Investment Risks
- Revenue stagnation at +0.0% YoY indicates lack of organic growth momentum and potential market saturation
- Elevated debt-to-equity ratio of 1.13x combined with $589.7M long-term debt creates financial risk if profitability declines
- Modest ROE of 10.1% and ROA of 4.0% suggest suboptimal capital deployment and returns generation
- Significant insider activity (17 Form 4 filings in 90 days) may signal uncertainty about company direction
- Net margin of 7.1% is below peer benchmarks for pharmaceutical sector, indicating competitive pressure
- Revenue stagnation at $742.9M raises concern about how sustainable earnings growth will be without top-line expansion
- Leverage is still meaningful, with $589.7M of long-term debt and a 1.13x debt-to-equity ratio
- Interest coverage of 4.1x leaves less room for operational setbacks or margin compression
Key Metrics to Watch
- Revenue growth trajectory - must demonstrate organic growth to justify valuation and support debt
- Operating margin sustainability - monitor if 13.5% margin is maintainable or anomalous
- Free cash flow conversion and debt reduction - track deleveraging progress toward 0.8x Debt/Equity target
- Gross margin stability - ensure pricing power and product mix remain favorable
- ROE expansion - watch for improvement toward 12-15% industry benchmarks
- Revenue growth and segment mix improvement
- Debt reduction and interest coverage trend
Emergent BioSolutions Inc. (EBS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 21.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 5.01x current ratio provides a solid financial cushion.
EBS Profit Margin, ROE & Profitability Analysis
EBS vs Healthcare Sector: How Emergent BioSolutions Inc. Compares
How Emergent BioSolutions Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Emergent BioSolutions Inc. Stock Overvalued? EBS Valuation Analysis 2026
Based on fundamental analysis, Emergent BioSolutions Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Emergent BioSolutions Inc. Balance Sheet: EBS Debt, Cash & Liquidity
EBS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Emergent BioSolutions Inc.'s revenue has grown significantly by 34% over the 5-year period, indicating strong business expansion. The most recent EPS of $-14.85 indicates the company is currently unprofitable.
EBS Revenue Growth, EPS Growth & YoY Performance
EBS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $231.1M | $9.0M | $0.91 |
| Q2 2025 | $140.9M | $9.0M | $-0.22 |
| Q1 2025 | $222.2M | $9.0M | $0.17 |
| Q2 2021 | $394.7M | $4.6M | $0.09 |
| Q1 2021 | $192.5M | -$12.5M | $-0.24 |
| Q3 2020 | $311.8M | $7.6M | $0.15 |
| Q2 2020 | $243.2M | -$9.5M | $-0.18 |
| Q1 2020 | $190.6M | -$12.5M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Emergent BioSolutions Inc. Dividends, Buybacks & Capital Allocation
EBS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Emergent BioSolutions Inc. (CIK: 0001367644)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EBS
What is the AI rating for EBS?
Emergent BioSolutions Inc. (EBS) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (HOLD) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EBS's key strengths?
Claude: Exceptional net income growth of 127.6% YoY demonstrates operational leverage and margin expansion. Strong free cash flow generation of $156.8M with 21.1% FCF margin provides financial flexibility. ChatGPT: Strong free cash flow generation with $156.8M of free cash flow and a 21.1% FCF margin. Excellent near-term liquidity, supported by a 5.01x current ratio and $205.4M in cash.
What are the risks of investing in EBS?
Claude: Revenue stagnation at +0.0% YoY indicates lack of organic growth momentum and potential market saturation. Elevated debt-to-equity ratio of 1.13x combined with $589.7M long-term debt creates financial risk if profitability declines. ChatGPT: Revenue stagnation at $742.9M raises concern about how sustainable earnings growth will be without top-line expansion. Leverage is still meaningful, with $589.7M of long-term debt and a 1.13x debt-to-equity ratio.
What is EBS's revenue and growth?
Emergent BioSolutions Inc. reported revenue of $742.9M.
Does EBS pay dividends?
Emergent BioSolutions Inc. does not currently pay dividends.
Where can I find EBS SEC filings?
Official SEC filings for Emergent BioSolutions Inc. (CIK: 0001367644) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EBS's EPS?
Emergent BioSolutions Inc. has a diluted EPS of $0.93.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EBS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Emergent BioSolutions Inc. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is EBS stock overvalued or undervalued?
Valuation metrics for EBS: ROE of 10.1% (sector avg: 15%), net margin of 7.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EBS stock in 2026?
Our dual AI analysis gives Emergent BioSolutions Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EBS's free cash flow?
Emergent BioSolutions Inc.'s operating cash flow is $170.6M, with capital expenditures of $13.8M. FCF margin is 21.1%.
How does EBS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 7.1% (avg: 12%), ROE 10.1% (avg: 15%), current ratio 5.01 (avg: 2).